Enantiomer-specific activities of an LRH-1 and SF-1 dual agonist
Abstract Chirality is an important consideration in drug development: it can influence recognition of the intended target, pharmacokinetics, and off-target effects. Here, we investigate how chirality affects the activity and mechanism of action of RJW100, a racemic agonist of the nuclear receptors l...
Guardado en:
Autores principales: | Suzanne G. Mays, Józef Stec, Xu Liu, Emma H. D’Agostino, Richard J. Whitby, Eric A. Ortlund |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/bde5e80a95114cbbb7800f850e004f61 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
LRH-1 mitigates intestinal inflammatory disease by maintaining epithelial homeostasis and cell survival
por: James R. Bayrer, et al.
Publicado: (2018) -
LRH-1 agonism favours an immune-islet dialogue which protects against diabetes mellitus
por: Nadia Cobo-Vuilleumier, et al.
Publicado: (2018) -
The orphan nuclear receptor LRH-1 and ERα activate GREB1 expression to induce breast cancer cell proliferation.
por: Ashwini L Chand, et al.
Publicado: (2012) -
I1 imidazoline receptor: novel potential cytoprotective target of TVP1022, the S-enantiomer of rasagiline.
por: Yaron D Barac, et al.
Publicado: (2012) -
Pulsed electroconversion for highly selective enantiomer synthesis
por: Chularat Wattanakit, et al.
Publicado: (2017)